- Home
- SKT vs APGE Comparison
SKT vs APGE Comparison
Compare SKT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKT | APGE |
|---|---|---|
| Founded | 1981 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SKT | APGE |
|---|---|---|
| Price | $38.57 | $134.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $37.17 | ★ $109.67 |
| AVG Volume (30 Days) | 789.5K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.37 | N/A |
| Revenue Next Year | $3.90 | N/A |
| P/E Ratio | $73.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.13 | $35.39 |
| 52 Week High | $42.53 | $134.88 |
Technical Indicators
Market Signals| Indicator | SKT | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 77.39 |
| Support Level | $38.43 | $134.03 |
| Resistance Level | $41.27 | $134.88 |
| Average True Range (ATR) | 0.61 | 0.18 |
| MACD | -0.04 | -0.61 |
| Stochastic Oscillator | 40.00 | 95.24 |
Price Performance
Historical ComparisonAbout SKT Tanger Inc.
Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.